1
|
Liu X, Li S, Wang L, Ma K. Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment. Biochim Biophys Acta Mol Basis Dis 2024; 1870:167230. [PMID: 38734322 DOI: 10.1016/j.bbadis.2024.167230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 05/07/2024] [Accepted: 05/07/2024] [Indexed: 05/13/2024]
Abstract
The exploration of the complex mechanisms of cancer immunotherapy is rapidly evolving worldwide, and our focus is on the interaction of hepatocellular carcinoma (HCC) with immune checkpoint inhibitors (ICIs), particularly as it relates to the regulatory role of the gut microbiome. An important basis for the induction of immune responses in HCC is the presence of specific anti-tumor cells that can be activated and reinforced by ICIs, which is why the application of ICIs results in sustained tumor response rates in the majority of HCC patients. However, mechanisms of acquired resistance to immunotherapy in unresectable HCC result in no long-term benefit for some patients. The significant heterogeneity of inter-individual differences in the gut microbiome in response to treatment with ICIs makes it possible to target modulation of specific gut microbes to assist in augmenting checkpoint blockade therapies in HCC. This review focuses on the complex relationship between the gut microbiome, host immunity, and HCC, and emphasizes that manipulating the gut microbiome to improve response rates to cancer ICI therapy is a clinical strategy with unlimited potential.
Collapse
Affiliation(s)
- Xuliang Liu
- Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Shiyao Li
- Department of Respiratory Medicine, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Liming Wang
- Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China; Engineering Research Center for New Materials and Precision Treatment Technology of Malignant Tumors Therapy, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, China; Engineering Technology Research Center for Translational Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian, Liaoning, China.
| | - Kexin Ma
- Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
| |
Collapse
|
2
|
Li D, Li J, Liu H, Zhai L, Hu W, Xia N, Tang T, Jiao J, Lv B, Nie S, Hu D, Liao Y, Yang X, Shi G, Cheng X. Pathogenic Tconvs promote inflammatory macrophage polarization through GM‐CSF and exacerbate abdominal aortic aneurysm formation. FASEB J 2022; 36:e22172. [PMID: 35133017 PMCID: PMC9303938 DOI: 10.1096/fj.202101576r] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 12/30/2021] [Accepted: 01/10/2022] [Indexed: 01/05/2023]
Abstract
Abdominal aortic aneurysms (AAAs) elicit massive inflammatory leukocyte recruitment to the aorta. CD4+ T cells, which include regulatory T cells (Tregs) and conventional T cells (Tconvs), are involved in the progression of AAA. Tregs have been reported to limit AAA formation. However, the function and phenotype of the Tconvs found in AAAs remain poorly understood. We characterized aortic Tconvs by bulk RNA sequencing and discovered that Tconvs in aortic aneurysm highly expressed Cxcr6 and Csf2. Herein, we determined that the CXCR6/CXCL16 signaling axis controlled the recruitment of Tconvs to aortic aneurysms. Deficiency of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), encoded by Csf2, markedly inhibited AAA formation and led to a decrease of inflammatory monocytes, due to a reduction of CCL2 expression. Conversely, the exogenous administration of GM‐CSF exacerbated inflammatory monocyte infiltration by upregulating CCL2 expression, resulting in worsened AAA formation. Mechanistically, GM‐CSF upregulated the expression of interferon regulatory factor 5 to promote M1‐like macrophage differentiation in aortic aneurysms. Importantly, we also demonstrated that the GM‐CSF produced by Tconvs enhanced the polarization of M1‐like macrophages and exacerbated AAA formation. Our findings revealed that GM‐CSF, which was predominantly derived from Tconvs in aortic aneurysms, played a pathogenic role in the progression of AAAs and may represent a potential target for AAA treatment.
Collapse
Affiliation(s)
- Dan Li
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Jingyong Li
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Henan Liu
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Luna Zhai
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Wangling Hu
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Ni Xia
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Tingting Tang
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Jiao Jiao
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Bingjie Lv
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Shaofang Nie
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Desheng Hu
- Department of Integrated Traditional Chinese and Western Medicine Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Institute of Hematology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Yuhua Liao
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Xiangping Yang
- School of Basic Medicine Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| | - Guo‐Ping Shi
- Department of Medicine Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts USA
| | - Xiang Cheng
- Department of Cardiology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Key Laboratory for Biological Targeted Therapy of Education Ministry and Hubei Province Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China
| |
Collapse
|
3
|
Saxena S, Singh RK. Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity. Cancer Metastasis Rev 2021; 40:447-476. [PMID: 33959849 PMCID: PMC9863248 DOI: 10.1007/s10555-021-09970-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 04/22/2021] [Indexed: 01/26/2023]
Abstract
Chemokines, a subfamily of the cell cytokines, are low molecular weight proteins known to induce chemotaxis in leukocytes in response to inflammatory and pathogenic signals. A plethora of literature demonstrates that chemokines and their receptors regulate tumor progression and metastasis. With these diverse functionalities, chemokines act as a fundamental link between the tumor cells and their microenvironment. Recent studies demonstrate that the biology of chemokines and their receptor in metastasis is complex as numerous chemokines are involved in regulating site-specific tumor growth and metastasis. Successful treatment of disseminated cancer is a significant challenge. The most crucial problem for treating metastatic cancer is developing therapy regimes capable of overcoming heterogeneity problems within primary tumors and among metastases and within metastases (intralesional). This heterogeneity of malignant tumor cells can be related to metastatic potential, response to chemotherapy or specific immunotherapy, and many other factors. In this review, we have emphasized the role of chemokines in the process of metastasis and metastatic heterogeneity. Individual chemokines may not express the full potential to address metastatic heterogeneity, but chemokine networks need exploration. Understanding the interplay between chemokine-chemokine receptor networks between the tumor cells and their microenvironment is a novel approach to overcome the problem of metastatic heterogeneity. Recent advances in the understanding of chemokine networks pave the way for developing a potential targeted therapeutic strategy to treat metastatic cancer.
Collapse
Affiliation(s)
- Sugandha Saxena
- Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE, 68198-5900, USA
| | - Rakesh K Singh
- Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE, 68198-5900, USA.
| |
Collapse
|